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OBJECTIVES The purpose of this study was to assess the effects of L-arginine and NG-nitro-L-arginine
methyl ester (L-NAME) on neointimal hyperplasia and vascular remodeling after balloon
angioplasty in the hypercholesterolemic rabbit.
BACKGROUND Restenosis after balloon angioplasty is a consequence of both neointimal hyperplasia and
vessel remodeling. Nitric oxide inhibits neointimal hyperplasia, but its effect on vessel
remodeling is unknown.
METHODS Six weeks after induction of bilateral iliac atherosclerosis, 48 rabbits underwent successful
angioplasty in 75 vessels. Eight rabbits (acute group) were sacrificed immediately after
angioplasty. The remaining animals received either placebo (chronic control group), or a diet
supplemented with either L-arginine (1.5 g/kg/day), or L-NAME (15 mg/kg/day) for 4
weeks after angioplasty.
RESULTS The intimal area was significantly greater in the chronic control group compared to the acute
group (2.60 6 1.03 mm2 vs. 1.35 6 0.62 mm2). This increase in intimal area was lower in
the L-arginine group (1.79 6 0.61 mm2), and greater in the L-NAME group (3.23 6
0.92 mm2). The area circumscribed by the internal elastic lamina (IEL) increased significantly
in the control group compared to the acute group (from 2.52 6 0.66 to 3.33 6 0.85 mm2);
a more marked increase occurred in the L-NAME group (3.90 6 0.85 mm2). By contrast,
IEL area was unchanged in the L-arginine group (2.41 6 0.62 mm2). As a result, there was
no significant difference in lumen area after 4 weeks in the chronic groups (control: 0.74 6
0.38 mm2; L-arginine: 0.50 6 0.43 mm2; L-NAME: 0.48 6 0.42 mm2).
CONCLUSIONS Our results demonstrate that L-arginine inhibits whereas L-NAME stimulates neointimal
hyperplasia after experimental balloon angioplasty in the hypercholesterolemic rabbit.
However, the lack of vessel enlargement in the L-arginine group resulted in a similar final
lumen size in the L-NAME and L-arginine groups. (J Am Coll Cardiol 1999;33:876–82)
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There has been considerable interest in the potential role of
nitric oxide (NO) in restenosis after experimental angio-
plasty. Studies performed in rats or in rabbits have shown
that administration of L-arginine or of NO donors, or the
inhalation of NO are associated with a decrease in neoin-
timal hyperplasia after arterial injury (1–7). Moreover,
administration of the NO synthase inhibitor NG-nitro-L-
arginine methyl ester (L-NAME), has been associated with
an increase in neointimal hyperplasia (2). Nitric oxide has
thus been proposed as a potential “antirestenotic” molecule
that may act by inhibition of smooth muscle cell prolifera-
tion and migration, by inhibition of the synthesis of extra-
cellular matrix or by modulation of platelet and leukocyte
function (8–15).
However, recent studies, performed in experimental
models (16–20) and in humans (21,22), have shown that
neointimal hyperplasia is not the sole factor implicated in
restenosis and have demonstrated the major role of vascular
remodeling. Studies performed in the atherosclerotic rabbit
model have shown that vascular remodeling, not neointimal
hyperplasia, was the main determinant of restenosis (17,18).
Although it has been speculated that NO may be impli-
cated in vascular remodeling (23), its role in the adaptative
remodeling process that occurs after angioplasty has never
been specifically studied. We thus designed the present
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study to analyze the role of NO in restenosis after experi-
mental angioplasty in the hypercholesterolemic rabbit. The
effects of L-arginine and L-NAME on both neointimal
hyperplasia and vascular remodeling were studied.
METHODS
Male New Zealand White rabbits (3 to 3.5 kg) were used
for this study. The investigation conformed to the guide-
lines of the American Physiological Society for the care and
use of laboratory animals.
Induction of atherosclerosis. Bilateral iliac atherosclerosis
was induced as previously described (17,24). The animals
were anesthetized by intravenous injection of ethyl carbam-
ate, 1 g/kg via a marginal ear vein. After exposure of the
distal femoral arteries, a 3-F Fogarty balloon catheter was
retrogradely inserted 20 cm and inflated until contact was
made with the arterial wall. Deendothelialization of both
iliac arteries was accomplished by advancing and withdraw-
ing the catheter three times. The catheter was then re-
moved, the distal femoral arteries were ligated, and the
wound was closed. All rabbits received amoxycillin
(50 mg/kg intramuscularly) and were fed a high cholesterol
(2%) diet until sacrifice.
Angiography and balloon angioplasty. Six weeks after
induction of atherosclerosis, the animals were anesthetized
as described above. During the experimental procedure
anesthesia was maintained by intermittent intravenous in-
jection of ethyl carbamate 250 mg/kg. The right carotid
artery was isolated by blunt dissection through a midline
neck incision. A 5-F arterial sheath was then introduced via
an arteriotomy and advanced to the abdominal aorta under
fluoroscopic guidance. Angiograms were obtained with a
Philips 17-cm image intensifier with a resolution of 4.4 line
pairs per millimeter. Three minutes after administration of
isosorbide dinitrate (ISDN; 0.2 mg), a baseline angiogram
was recorded on videotape by injection of 3 ml of contrast
medium (ioxaglate meglumine). A radio-opaque grid was
placed over the pelvis to permit correction for magnification.
Angioplasty was performed if a 50% to 99% iliac stenosis
was present, as estimated visually from the angiogram.
The angioplasty procedure was performed after adminis-
tration of heparin (100 IU/kg). Under fluoroscopic guid-
ance, a 0.014 in. (0.0355 cm) guide wire was inserted
through the introducer sheath and advanced to the external
iliac artery. A conventional balloon angioplasty catheter
(2.5 mm in diameter, 20 mm long) was advanced to the site
of the most severe iliac artery stenosis. Three 60-s inflations
were performed at a pressure of 6 atmospheres, with a
1-min interval between each inflation. The result of the
angioplasty procedure was documented by a second angio-
gram (3 min after administration of 0.2 mg of ISDN). The
catheters were then removed, the arteries were ligated and
amoxycillin (50 mg/kg intramuscularly) was administered.
Successful angioplasty was defined as a .20% decrease in
percent diameter stenosis.
Study groups. Fifty animals had unilateral or bilateral iliac
stenoses and underwent angioplasty (Fig. 1). Successful iliac
angioplasty was performed at 75 lesions in 48 rabbits. Eight
rabbits (the acute group, 15 vessels) were sacrificed imme-
diately after angioplasty. The iliac arteries were fixed by
perfusion in situ with 4% paraformaldehyde (in a saline
phosphate buffer solution) at 100 mm Hg for 30 min via a
catheter introduced into the aorta. The aorta and iliac
arteries were then removed and placed in 4% paraformal-
dehyde for 24 h. Forty rabbits (the chronic groups) were
allowed to recover and were maintained on the 2% choles-
terol diet for 4 weeks. Immediately after angioplasty, these
animals were randomized into three groups: 14 rabbits
received placebo (the chronic control group, 20 vessels); 12
rabbits received 1.5 g/kg/day of L-arginine hydrochloride
(Sigma Chemical Co.) in the drinking water (the
L-arginine group, 19 vessels), and 14 rabbits received 15
mg/kg/day of L-NAME (Sigma Chemical Co.) in the
drinking water (the L-NAME group, 21 vessels). The dose
of L-arginine was chosen because it has already been
demonstrated to be effective in reducing neointimal hyper-
plasia in rabbit iliac arteries (3,4). The dose of L-NAME
was chosen because it has been used in rabbits, by either oral
or subcutaneous administration, without effect on arterial
blood pressure (25,26). Six animals (one in the placebo
group, three in the L-arginine group and two in the
L-NAME group) died during the follow-up period. After 4
weeks, animals of the chronic groups (13 [19 vessels] in the
Abbreviations and Acronyms
EEL 5 external elastic lamina
IEL 5 internal elastic lamina
ISDN 5 isosorbide dinitrate
L-NAME 5 NG-nitro-L-arginine methyl ester
NO 5 nitric oxide
Figure 1. Study design. L-NAME 5 NG-nitro-L-arginine
methyl ester.
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placebo group, 9 [14 vessels] in the L-arginine group and 12
[18 vessels] in the L-NAME group) underwent angiogra-
phy as described above and were sacrificed. The arteries
were perfusion-fixed, removed and placed in 4% parafor-
maldehyde in the same manner as the acute group.
Biochemical and physiologic measurements. Blood sam-
ples for determination of cholesterol levels were obtained at
the time of angioplasty in all four study groups, and at the
time of sacrifice in the chronic groups. Plasma cholesterol
levels were measured with a Ciba-Corning 550 Express
spectrophotometer using a commercially available enzy-
matic assay (Bio Me´rieux).
In the chronic groups, blood samples were obtained at the
time of sacrifice for measurement of plasma-free arginine
levels. Plasma was deproteinized with 10% sulfosalicylic acid
and analyzed for free arginine with an automated amino-
acid analyzer (model LC 300, Biotronic Instruments).
Blood pressure was measured under general anesthesia via
the catheter inserted into the carotid artery, in all groups
immediately before angioplasty, and at the time of sacrifice
in the three chronic groups.
Angiographic analysis. The reference diameters (a proxi-
mal angiographically normal segment of the external iliac
artery and a segment of the common iliac artery) and the
minimal lumen diameter were measured with calipers.
Absolute diameters were calculated by correcting for mag-
nification with the use of the radio-opaque grid. The
measurements were performed in all groups immediately
before and immediately after angioplasty, and in the three
chronic groups at the time of the final angiogram.
Histological analysis. After review of the angiograms to
guide sampling, a 10-mm long segment of the artery
including the lesion was cut into three 3- to 4-mm long
pieces, which were embedded in paraffin. Cross sections
were taken at three locations (top, bottom, middle) within
each block. Thus a total of nine sections were analyzed for
each vessel. The sections were stained with Van Gieson
elastin.
Morphometric analysis of the histologic cross sections
was performed with a digital microscopic planimetry system
(SMC 2002, Bioblock Scientific). For each lesion, the
section that demonstrated the smallest lumen area was
selected for further analysis. Lumen area, intimal area,
medial area and the areas circumscribed by the internal
elastic lamina (IEL) and the external elastic lamina (EEL)
were measured by a pathologist who was unaware of the
study design.
Statistical analysis. Data are expressed as mean 6 SD.
Differences between groups were assessed with use of
analysis of variance and Scheffe´ test for multiple compari-
sons. For differences between two groups, Students t tests
were used. A value of p , 0.05 was considered statistically
significant. The sample size of the study groups was deter-
mined to give a power of 80% to detect a 40% increase in
lumen area in the L-arginine group versus the chronic
control group assuming a lumen area of 0.75 6 0.32 mm2 in
control rabbits as seen in a preliminary study with this
model in our laboratory.
RESULTS
Biochemical and physiologic measurements. As shown
in Table 1, plasma cholesterol levels were similar among the
four groups at the time of angioplasty and similar among the
three chronic groups at the time of sacrifice. Plasma arginine
levels were significantly higher in animals whose diet was
supplemented with L-arginine compared with control ani-
mals. There were no significant differences in blood pressure
measurements among the four groups at the time of
angioplasty and among the three chronic groups at the time
of sacrifice.
Angiography. Table 2 shows the angiographic results be-
fore angioplasty, immediately after angioplasty and at four-
week follow-up in the four study groups. There was no
significant difference in minimal lumen diameter before or
immediately after angioplasty among the four groups. The
reference vessel diameters were also similar among groups.
At four-week follow-up, a significant decrease in minimal
lumen diameter was observed in the three chronic groups,
Table 1. Biochemical and Physiologic Parameters
Acute Group Chronic Groups
Control
(n 5 8)
Control
(n 5 13)
L-arginine
(n 5 9)
L-NAME
(n 5 12)
Plasma cholesterol (g/liter)
Preangioplasty 35 6 11 29 6 8 28 6 8 27 6 8
Sacrifice — 28 6 9 27 6 8 28 6 9
Plasma L-arginine (mmol/liter) — 114 6 27 366 6 195* 125 6 23
Mean arterial blood pressure (mm Hg)
Preangioplasty 111 6 8 113 6 11 117 6 16 114 6 10
Sacrifice — 103 6 17 101 6 13 101 6 12
*p , 0.001 vs. control.
L-NAME 5 NG-nitro-L-arginine methyl ester.
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whereas no change in reference vessel diameters was ob-
served. There was no significant difference in minimal
lumen diameter at follow-up among the three chronic
groups (control 5 0.82 6 0.37 mm, L-arginine 5 0.63 6
0.47 mm, L-NAME 5 0.58 6 0.46 mm).
Morphometry. Table 3 shows the morphometric results of
the acute and chronic groups. In the control group, we
observed a significant increase in intimal area compared to
the acute group (from 1.35 6 0.62 to 2.60 6 1.03 mm2).
This increase in intimal area was lower in the L-arginine
group (1.79 6 0.61 mm2), and greater in the L-NAME
group (3.23 6 0.92 mm2).
There was no significant difference in medial area among
the four groups, although there was a trend for an increase
in the L-NAME group.
In the control group, we observed a significant increase in
the area circumscribed by the IEL or in the area circum-
scribed by the EEL compared with the acute group (from
2.52 6 0.66 to 3.33 6 0.85 mm2 and from 3.23 6 0.83 to
4.04 6 0.92 mm2, respectively). By contrast, in the
L-arginine group, no increase in IEL or EEL area was
observed (2.41 6 0.62 mm2 and 3.12 6 0.78 mm2,
respectively). On the other hand, in the L-NAME group, a
greater increase in IEL or EEL area was observed (3.90 6
0.85 mm2 and 4.81 6 1.06 mm2, respectively).
There was no significant difference in lumen area at
4-week follow-up among the three groups. The changes in
lumen area during the follow-up period reflected both
changes in intimal area and changes in vessel size. In the
control group, the increase in IEL area accommodated 67%
of the increase in intimal area (1.25 mm2) over the same
time period; as a result, lumen area decreased only by
0.43 mm2. In the L-arginine group, the potentially benefi-
cial effect of the decrease in intimal area on lumen area was
completely reversed by the lack of enlargement of the vessel.
By contrast, in the L-NAME group, the increase in
neointimal area was compensated by the greater degree of
vessel enlargement.
Twelve vessels (two in the control group, four in the
L-arginine group and six in the L-NAME group) were
totally occluded at follow-up. In eight cases, a thrombus was
clearly identifiable on the histologic cross sections. For these
Table 2. Angiographic Results Before and After Angioplasty
Acute Group Chronic Groups
Control
(n 5 15)
Control
(n 5 19)
L-arginine
(n 5 14)
L-NAME
(n 5 18)
Preangioplasty
MLD (mm) 0.80 6 0.28 0.82 6 0.31 0.84 6 0.30 0.73 6 0.18
Reference EIA (mm) 1.61 6 0.17 1.63 6 0.23 1.68 6 0.22 1.67 6 0.17
Reference CIA (mm) 1.83 6 0.27 1.85 6 0.31 1.91 6 0.63 1.94 6 0.46
Postangioplasty
MLD (mm) 1.47 6 0.29 1.45 6 0.28 1.50 6 0.28 1.48 6 0.22
Reference EIA (mm) 1.72 6 0.17 1.70 6 0.25 1.73 6 0.16 1.74 6 0.14
Reference CIA (mm) 1.85 6 0.30 1.92 6 0.31 2.00 6 0.55 2.13 6 0.47
Follow-up
MLD (mm) — 0.82 6 0.37 0.63 6 0.47 0.58 6 0.46
Reference EIA (mm) — 1.68 6 0.16 1.66 6 0.18 1.69 6 0.19
Reference CIA (mm) — 1.78 6 0.32 1.87 6 0.48 1.81 6 0.51
CIA 5 common iliac artery; EIA 5 external iliac artery; L-NAME 5 NG-nitro-L-arginine methyl ester; MLD 5 minimal
lumen diameter; Reference 5 diameter of angiographically normal segment.
Table 3. Morphometric Analysis
Acute Group Chronic Groups
Control
(n 5 15)
Control
(n 5 19)
L-arginine
(n 5 14)
L-NAME
(n 5 18)
Intimal area (mm2) 1.35 6 0.62 2.60 6 1.03* 1.79 6 0.61 3.23 6 0.92*†
Medial area (mm2) 0.70 6 0.31 0.71 6 0.18 0.71 6 0.27 0.91 6 0.45
IEL area (mm2) 2.52 6 0.66 3.33 6 0.85* 2.41 6 0.62‡ 3.90 6 0.85*†
EEL area (mm2) 3.23 6 0.83 4.04 6 0.92* 3.12 6 0.78 4.81 6 1.06*†
Lumen area (mm2) 1.17 6 0.31 0.74 6 0.38* 0.50 6 0.43* 0.48 6 0.42*
*p , 0.05 vs. acute control group. †p , 0.05 vs. L-arginine. ‡p , 0.05 vs. chronic control group. Thrombus in three vessels in
the L-arginine group and in five vessels in the L-NAME group accounts for the discrepancy between lumen1intimal area and
IEL area.
EEL area 5 area circumscribed by external elastic lamina; IEL area 5 area circumscribed by internal elastic lamina;
L-NAME 5 NG-nitro-L-arginine methyl ester.
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vessels, thrombus area was not included in intimal area; our
results were, however, not altered if thrombus was measured
as intimal area (data not shown). Similarly, a reanalysis of
morphometric measurements after exclusion of the vessels
with total occlusion at follow-up did not alter our results
(data not shown).
DISCUSSION
The present study, performed in the atherosclerotic rabbit
model, demonstrates that animals treated with L-arginine
after balloon angioplasty have less marked neointimal hy-
perplasia than control animals, whereas animals treated with
L-NAME have more marked neointimal hyperplasia.
However, because vessel enlargement was observed in the
L-NAME group but not in the L-arginine group, neither
drug had a significant effect on the final lumen size.
Mechanisms of restenosis. Restenosis after balloon angio-
plasty has been traditionally associated with neointimal
hyperplasia (27–29). Proliferation and migration of smooth
muscle cells have been documented after experimental
balloon angioplasty, in various species and in single-injury
or double-injury models including the atherosclerotic rabbit
model (20,27,30,31). Moreover, it has been shown that
synthetic smooth muscle cells produce extracellular matrix
proteins that constitute a large proportion of the neointimal
volume. Neointimal hyperplasia has also been documented
in humans; histologic studies have shown that intimal
thickening in the restenotic lesion contains smooth muscle
cells in an abundant extracellular matrix (28,29).
However, the lack of effect in humans of drugs that
markedly inhibited neointimal hyperplasia in experimental
models led to a reappraisal of the mechanisms of restenosis.
Recently, concordant studies have been published showing
that lumen renarrowing after angioplasty was also due to
vascular remodeling (16–20). In the atherosclerotic rabbit
model, Kakuta et al. and Lafont et al. demonstrated that
vascular remodeling was the main determinant of lumen size
at follow-up (i.e., restenosis) (17,18). In these studies, a
linear correlation was observed between neointimal (or
neointimal plus medial) area and vessel size (i.e., area
circumscribed by the IEL or the EEL), suggesting that an
increase in vessel size may compensate a large proportion of
intimal growth. Our results are concordant with these
previous studies; in the control groups, we found a signifi-
cant enlargement in vessel size from immediately after
angioplasty to sacrifice 4 weeks later; this increase in vessel
size was able to accommodate 67% of the increase in intimal
area over the same time period.
Importantly, vessel remodeling has also been confirmed
as a major determinant of restenosis after angioplasty in
humans (21,22). This may, at least in part, explain why
drugs that effectively prevented neointimal hyperplasia in
experimental models consistently failed to prevent restenosis
in the clinical setting. In the light of these new findings on
the mechanisms of restenosis, it is thus important to
reevaluate drugs that have to date only been shown to affect
neointimal hyperplasia. Indeed, depending upon their effect
on vessel remodeling, these drugs may actually decrease
restenosis, have no effect on restenosis or even increase
restenosis.
The NO pathway and neointimal hyperplasia. Previous
studies, performed in single-injury models, have shown that
the NO pathway is an important determinant of neointimal
hyperplasia after experimental angioplasty (1–3,7). Admin-
istration of L-arginine (the substrate for the enzyme NO
synthase), administration of NO donors and inhalation of
NO have been associated with an inhibition of neointimal
hyperplasia in rats and rabbits (1–7). Conversely, adminis-
tration of NO synthase inhibitors, such as L-NAME, has
been associated with an increase in neointimal hyperplasia
(2). To date, however, no data are available concerning the
impact of the NO pathway in double-injury models such as
the hypercholesterolemic rabbit. This model differs from
single-injury models by the fact that angioplasty is per-
formed on an already diseased vessel and by the number of
foam cells in the neointimal thickening (24,30); this model
may thus better reflect what could occur in human arteries.
Our results clearly show that L-arginine has an inhibitory
effect on neointimal hyperplasia, whereas the NO synthase
inhibitor L-NAME has a stimulatory effect. Our results are
thus concordant with those obtained in single-injury mod-
els. The mechanisms by which NO affects neointimal
hyperplasia are not entirely clear but may relate to an
inhibition of smooth muscle cell proliferation and migration
(9–11), to an inhibition of extracellular matrix components
production (12) or to a modulation of platelet and leukocyte
functions (13–15).
The NO pathway and vessel remodeling. The production
of endogenous vasodilators such as NO has been implicated
in vessel remodeling (23). In an arteriovenous fistula model,
chronic administration of L-NAME has been associated
with decreased vascular enlargement, thereby suggesting
that NO may participate in flow-induced remodeling of the
rabbit common carotid artery (32). We thus speculated that
NO might also participate in other forms of vessel remod-
eling such as remodeling after balloon angioplasty.
Vessel remodeling after balloon angioplasty may be de-
scribed as a spectrum of changes in total vessel area ranging
from constriction to enlargement. The model used in the
present study does not allow us to analyze the exact
mechanisms of vessel remodeling; our specific aim was to
describe the effects of the NO pathway on vessel size at the
lesion site and consequently, taking into account its effects
on neointimal hyperplasia, to assess its effects on lumen size.
L-arginine–treated animals had no change in vessel size,
whereas L-NAME–treated animals had a major increase in
vessel size. This observation conflicts with the hypothesis
that NO could induce vascular enlargement after angio-
plasty. One possible explanation for these unexpected find-
ings may be that the significant effects of L-arginine and
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L-NAME on neointimal hyperplasia could have an impact
on vessel remodeling. Previous studies have suggested that
the extent of neointimal formation may be an important
determinant of vessel enlargement after angioplasty (17,18),
the inhibitory effect of L-arginine on neointimal formation
may thus indirectly inhibit vessel enlargement; conversely,
the stimulatory effect of L-NAME on neointimal formation
may indirectly stimulate vessel enlargement. Whatever is
the explanation for our findings, these results demonstrate
that despite significant effects on neointimal growth, stim-
ulation or inhibition of the NO pathway has no impact on
final lumen size in this experimental model. These results
underscore the importance of studying “antirestenosis”
drugs in experimental models where the effects of both
neointimal hyperplasia and vessel remodeling can be ade-
quately assessed.
There are several limitations to this study. First, as stated
above, this model is limited by the lack of a reference
nondilated segment for calculation of relative values; this
precludes a careful analysis of the mechanisms of the
changes in vessel size (i.e., constrictive remodeling vs. lack
of enlargement). Second, restenosis is a dynamic process,
and both neointimal hyperplasia and vascular remodeling
are time-related phenomena. This study used a 4-week time
point, which has been the end point of most investigators
studying neonintimal hyperplasia and vascular remodeling
in similar models (17,18); further time course experiments
may provide additional information. Finally, our conclusion
that the NO pathway had no impact on experimental
restenosis may not apply to vascular stents. It has been
shown that restenosis after stent implantation may be
affected more by neointima, formation rather than vascular
remodeling (33). In this instance, targeting the NO pathway
to reduce neointimal formation would be important.
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